(4-(Pyridin-2-yl)phenyl)methanamine hydrochloride, 95.0%, 250mg

1-Bromo-4,5-difluoro-3-ethoxybenzene, 97.0%, 1g

2,6-Dimethylphenyl (2,4-dimethoxyphenyl)(2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)carbamate, 98%, 5mg

(2'-CHLOROBIPHENYL-4-YL)METHANAMINE, 95.0%, 1g

2-(Difluoromethyl)-5-iodopyridine, 98%, 250mg

1,5-Dimethoxynaphthalene, 95.0%, 5g

1,4-Diiodo-2,3,5,6-tetramethylbenzene, 95.0%, 5g

2-Chloro-3-methylaniline, 95.0%, 1g

tert-Butyl 2'-(((trifluoromethyl)sulfonyl)oxy)-5',6'-dihydrospiro[pyrrolidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate, 98%, 500mg

5-Fluoro-1,3-dimethyl-2-nitrobenzene, 95.0%, 1g

Plan phase PLPHi 10x/0,25 objectif IOS corrigé à l'infini. Distance de travail 5,00 mm

4-Methyl-3,4-dihydro-2H-benzo[1,4]oxazine, 95.0%, 100mg

3-Ethyl-3-oxetanemethanol>96.0%(GC)25g